Movatterモバイル変換
[0]
ホーム
URL:
画像なし
夜間モード
Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Community portal
Project chat
Create a new Item
Recent changes
Random Item
Query Service
Nearby
Help
Special pages
Lexicographical data
Create a new Lexeme
Recent changes
Random Lexeme
Search
Search
English
Appearance
Donate
Create account
Log in
Personal tools
Donate
Create account
Log in
Pages for logged out editors
learn more
Contributions
Talk
fosinopril
(Q425293)
Item
Discussion
English
Read
View history
Tools
Tools
move to sidebar
hide
Actions
Read
View history
General
What links here
Related changes
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Concept URI
Print/export
Create a book
Download as PDF
Printable version
In other projects
Appearance
move to sidebar
hide
From Wikidata
mixture of stereoisomers
(S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
edit
Language
Label
Description
Also known as
default for all languages
No label defined
–
SQ-28555
C30H46N1O7S1
English
fosinopril
mixture of stereoisomers
(S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(2S,4S)-4-cyclohexyl-1-{2-[(2-methyl-1-propionyloxy-propoxy)-(4-phenyl-butyl)-phosphinoyl]-acetyl}-pyrrolidine-2-carboxylic acid
(2S,4S)-4-cyclohexyl-1-[2-[(2-methyl-1-propanoyloxypropoxy)-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid
Statements
instance of
group of stereoisomers
0 references
subclass of
N,N-disubstituted primary carboxamide
0 references
monocarboxylic acid
0 references
propionate ester
0 references
pyrrolidine
0 references
phosphinate ester
0 references
has use
medication
0 references
chemical structure
Fosinopril structure.svg
512 × 368; 7 KB
0 references
mass
563.301189
dalton
1 reference
stated in
PubChem
PubChem CID
55891
language of work or name
English
title
fosinopril
(English)
retrieved
20 September 2016
chemical formula
C₃₀H₄₆NO₇P
1 reference
stated in
PubChem
PubChem CID
55891
language of work or name
English
title
fosinopril
(English)
retrieved
20 September 2016
canonical SMILES
CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2CC(CC2C(=O)O)C3CCCCC3
0 references
isomeric SMILES
CCC(=O)OC(OP(=O)(CCCCc1ccccc1)CC(=O)N1C[C@H](C2CCCCC2)C[C@H]1C(=O)O)C(C)C
1 reference
based on heuristic
inferred from InChI
defined daily dose
15
milligram
route of administration
oral administration
1 reference
reference URL
https://www.whocc.no/atc_ddd_index/?code=C09AA09
active ingredient in
Monopril
1 reference
stated in
RxNorm
RxNorm ID
225030
retrieved
14 February 2018
medical condition treated
congestive heart failure
1 reference
stated in
NDF-RT
NDF-RT ID
N0000148247
language of work or name
English
retrieved
13 December 2016
arterial hypertension
2 references
stated in
NDF-RT
NDF-RT ID
N0000148247
language of work or name
English
retrieved
13 December 2016
stated in
Drug Indications Extracted from FAERS
retrieved
2 October 2018
arterial hypertension
start time
30 November 2003
approved by
Food and Drug Administration
1 reference
stated in
Inxight: Drugs Database
retrieved
2 November 2018
reference URL
https://www.drugs.com/pro/fosinopril.html
significant drug interaction
valsartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
telmisartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eprosartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
irbesartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
candesartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
losartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
olmesartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
azilsartan
side effect
hypotension
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eplerenone
side effect
hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
(RS)-bendroflumethiazide
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
chlorthalidone
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
(2RS,6RS)-clopamide
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
bromocriptine
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
bumetanide
side effect
hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
furosemide
side effect
hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
spironolactone
side effect
hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
hydrochlorothiazide
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
indapamide
side effect
hypotension
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
valsartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
valsartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
valsartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
valsartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
telmisartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
telmisartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
telmisartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
telmisartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eprosartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eprosartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eprosartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eprosartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
irbesartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
irbesartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
irbesartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
irbesartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
candesartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
candesartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
candesartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
candesartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
losartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
losartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
losartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
losartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
olmesartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
olmesartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
olmesartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
olmesartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
azilsartan
side effect
acute kidney injury
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
azilsartan
side effect
hyperkalemia
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
azilsartan
side effect
syncope
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
azilsartan
side effect
kidney failure
1 reference
sourcing circumstances
established
stated in
A reference set of clinically relevant adverse drug-drug interactions
eplerenone
side effect
hyperkalemia
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
spironolactone
side effect
hyperkalemia
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
(RS)-bendroflumethiazide
side effect
decreased blood pressure
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
chlorthalidone
side effect
decreased blood pressure
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
(2RS,6RS)-clopamide
side effect
decreased blood pressure
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
hydrochlorothiazide
side effect
decreased blood pressure
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
indapamide
side effect
decreased blood pressure
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
bromocriptine
side effect
hyperinsulinism
1 reference
sourcing circumstances
hypothetically
stated in
A reference set of clinically relevant adverse drug-drug interactions
bumetanide
side effect
orthostatic hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
furosemide
side effect
orthostatic hypotension
1 reference
sourcing circumstances
probably
stated in
A reference set of clinically relevant adverse drug-drug interactions
legal status (medicine)
boxed warning
1 reference
reference URL
https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802
title
FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.
(English)
pregnancy category
Australian pregnancy category D
1 reference
imported from Wikimedia project
English Wikipedia
US pregnancy category C
1 reference
imported from Wikimedia project
English Wikipedia
subject has role
ACE inhibitor
2 references
stated in
NDF-RT
NDF-RT ID
N0000148247
retrieved
5 March 2018
stated in
Medical Subject Headings
MeSH descriptor ID
D017328
retrieved
15 March 2018
antihypertensive drug
1 reference
stated in
Medical Subject Headings
MeSH descriptor ID
D017328
retrieved
15 March 2018
NCI Thesaurus ID
C65761
1 reference
stated in
Global Substance Registration System
UNII
R43D2573WO
retrieved
15 February 2018
has part(s)
nitrogen
0 references
carbon
0 references
Commons category
Fosinopril
0 references
Identifiers
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
1 reference
stated in
PubChem
PubChem CID
55891
language of work or name
English
title
fosinopril
(English)
retrieved
20 September 2016
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
2 references
stated in
PubChem
PubChem CID
55891
language of work or name
English
title
fosinopril
(English)
retrieved
20 September 2016
stated in
ChEBI release 2020-09-01
CAS Registry Number
98048-97-6
2 references
stated in
DrugBank
DrugBank ID
DB00492
language of work or name
English
title
Fosinopril
(English)
publication date
17 November 2015
stated in
Global Substance Registration System
UNII
R43D2573WO
retrieved
15 February 2018
ChemSpider ID
50469
1 reference
stated in
ChemSpider
ChemSpider ID
50469
language of work or name
English
title
(4S)-4-cyclohexyl-1-({[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)-L-proline
(English)
retrieved
20 September 2016
PubChem CID
55891
2 references
stated in
PubChem
PubChem CID
55891
language of work or name
English
title
fosinopril
(English)
retrieved
20 September 2016
matched by identifier from
InChIKey
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
Reaxys registry number
8176492
0 references
ChEBI ID
5163
mapping relation type
exact match
2 references
stated in
ChEMBL
ChEMBL ID
CHEMBL3306578
language of work or name
English
title
CHEMBL3306578
(English)
retrieved
20 September 2016
matched by identifier from
International Chemical Identifier
InChI
InChI=1S/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1
ChEMBL ID
CHEMBL3306578
1 reference
stated in
ChEMBL
ChEMBL ID
CHEMBL3306578
language of work or name
English
title
CHEMBL3306578
(English)
retrieved
20 September 2016
CHEMBL3039598
1 reference
stated in
ChEMBL
ChEMBL ID
CHEMBL3039598
language of work or name
English
title
FOSINOPRIL
(English)
retrieved
3 October 2016
SureChEMBL ID
SCHEMBL15626
2 references
based on heuristic
inferred from InChIKey
matched by identifier from
InChIKey
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
UniChem compound ID
1065574
1 reference
stated in
UniChem
MassBank accession ID
MSBNK-Athens_Univ-AU224701
0 references
MSBNK-Athens_Univ-AU224702
0 references
MSBNK-Athens_Univ-AU224703
0 references
MSBNK-Athens_Univ-AU224704
0 references
MSBNK-Athens_Univ-AU224705
0 references
MSBNK-Athens_Univ-AU224707
0 references
MSBNK-Athens_Univ-AU224708
0 references
MSBNK-Athens_Univ-AU224709
0 references
MSBNK-Athens_Univ-AU224710
0 references
MSBNK-Athens_Univ-AU224711
0 references
MSBNK-Athens_Univ-AU224734
0 references
MSBNK-Athens_Univ-AU224751
0 references
MSBNK-Athens_Univ-AU224752
0 references
MSBNK-Athens_Univ-AU224753
0 references
MSBNK-Athens_Univ-AU224754
0 references
MSBNK-Athens_Univ-AU224755
0 references
MSBNK-Eawag-EQ332401
0 references
MSBNK-Eawag-EQ332402
0 references
MSBNK-Eawag-EQ332403
0 references
MSBNK-Eawag-EQ332404
0 references
MSBNK-Eawag-EQ332405
0 references
MSBNK-Eawag-EQ332406
0 references
MSBNK-Eawag-EQ332451
0 references
MSBNK-Eawag-EQ332452
0 references
MSBNK-Eawag-EQ332453
0 references
MSBNK-Eawag-EQ332454
0 references
MSBNK-Eawag-EQ332455
0 references
MSBNK-Eawag-EQ332456
0 references
SPLASH
splash10-000i-0000900000-0eee13fe1a605e98c985
0 references
splash10-00ku-0105900000-1253dd1cea86dcfde7f6
0 references
splash10-0udl-0908200000-59ff4955c6e6b2d36435
0 references
splash10-0udi-0901000000-e2b0d1bb8bfd4d6f7595
0 references
splash10-014i-0000900000-f61a6a8a62cc0c92102b
0 references
splash10-014i-0000900000-ed280398ec57e4a02dce
0 references
splash10-00di-0090300000-4e1c300644a39a64aefe
0 references
splash10-00di-0090000000-85f8c80f83290feea35c
0 references
splash10-00di-0090000000-e28a43e299ff58e3a6bc
0 references
splash10-000i-0000900000-f625a00c8eb75cbf317d
0 references
splash10-0f6x-0409200000-5a18b8096c457898aa5f
0 references
splash10-0udi-0900000000-28e69824d7a0442561b6
0 references
splash10-0udi-0900000000-aa95f5f65aec2f92a48a
0 references
splash10-0udi-2900000000-48b3327e8691a43ae029
0 references
splash10-0udi-6900000000-de8ad752f1c8f05aded2
0 references
splash10-014i-0010900000-a142ed389f6652d197f1
0 references
splash10-00di-1090000000-833fa43a37b31e08737c
0 references
splash10-00di-1090000000-cda46913f10b57e39204
0 references
splash10-00di-2290000000-8627963d14d5d091e338
0 references
splash10-0229-7890000000-a5186e8ef5fa038d0a91
0 references
splash10-03k9-9720000000-ff0242177e3d4ef6c38a
0 references
DSSTox substance ID
DTXSID1023079
2 references
stated in
Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard
matched by identifier from
InChIKey
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
DSSTOX compound identifier
DTXCID003079
0 references
ATC code
C09AA09
1 reference
stated in
DrugBank
DrugBank ID
DB00492
language of work or name
English
title
Fosinopril
(English)
publication date
17 November 2015
Guide to Pharmacology Ligand ID
6456
1 reference
stated in
IUPHAR/BPS Guide to PHARMACOLOGY
retrieved
8 February 2021
MeSH descriptor ID
D017328
subject named as
Fosinopril
1 reference
stated in
Medical Subject Headings
MeSH descriptor ID
D017328
retrieved
14 March 2018
MeSH tree code
D02.705.629.500
0 references
D12.125.072.401.623.374
0 references
RxNorm ID
50166
1 reference
stated in
Global Substance Registration System
UNII
R43D2573WO
retrieved
15 February 2018
Human Metabolome Database ID
HMDB0014635
2 references
based on heuristic
inferred from InChIKey
matched by identifier from
InChIKey
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
UNII
R43D2573WO
2 references
stated in
NDF-RT
NDF-RT ID
N0000148247
language of work or name
English
title
FOSINOPRIL
(English)
retrieved
19 January 2016
stated in
Global Substance Registration System
UNII
R43D2573WO
retrieved
15 February 2018
8B3FLG23GN
1 reference
matched by identifier from
InChIKey
InChIKey
BIDNLKIUORFRQP-FKDWWROVSA-N
MedlinePlus drug identifier
a692020
0 references
PatientsLikeMe treatment ID
fosinopril
0 references
NDF-RT ID
N0000148247
1 reference
stated in
NDF-RT
NDF-RT ID
N0000148247
language of work or name
English
title
FOSINOPRIL
(English)
retrieved
19 January 2016
Probes And Drugs ID
PD009996
0 references
KEGG ID
D00622
1 reference
stated in
ChEMBL
ChEMBL ID
CHEMBL3306578
language of work or name
English
title
Fosinopril
(English)
retrieved
19 January 2016
DeCS ID
30725
0 references
Freebase ID
/m/038t1_
1 reference
stated in
Freebase Data Dumps
publication date
28 October 2013
KBpedia ID
Fosinopril
1 reference
stated in
KBpedia
retrieved
9 July 2020
Microsoft Academic ID
2780436477
0 references
OpenAlex ID
C2780436477
1 reference
stated in
OpenAlex
retrieved
26 January 2022
reference URL
https://docs.openalex.org/download-snapshot/snapshot-data-format
WikiProjectMed ID
Fosinopril
0 references
Sitelinks
Wikipedia
(24 entries)
edit
arwiki
فوزينوبريل
azbwiki
فوزینوپریل
cywiki
Ffosinopril
dewiki
Fosinopril
enwiki
Fosinopril
eswiki
Fosinopril
fawiki
فوزینوپریل
frwiki
Fosinopril
hrwiki
Fosinopril
huwiki
Fozinopril
idwiki
Fosinopril
itwiki
Fosinopril
mkwiki
Фосиноприл
nlwiki
Fosinopril
orwiki
ଫୋସିନୋପ୍ରିଲ
plwiki
Fozynopryl
ptwiki
Fosinopril
rowiki
Fosinopril
ruwiki
Фозиноприл
shwiki
Fosinopril
srwiki
Fosinopril
svwiki
Fosinopril
ukwiki
Фозиноприл
viwiki
Fosinopril
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(1 entry)
edit
commonswiki
Category:Fosinopril
Retrieved from "
https://www.wikidata.org/w/index.php?title=Q425293&oldid=2359773359
"
Search
Search
fosinopril
(Q425293)
Add topic
[8]
ページ先頭
©2009-2025
Movatter.jp